Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
LAVA Therapeutics NV | Chief Financial Officer | Share Options (Right to Buy) | 125K | Feb 13, 2025 | Direct | ||
LAVA Therapeutics NV | Chief Financial Officer | Common Shares | 65K | Jan 1, 2025 | Direct | ||
ANTARES PHARMA, INC. | Executive Vice President & CFO | Common Stock | 0 | $5.60 | May 24, 2022 | Direct | |
ANTARES PHARMA, INC. | Executive Vice President & CFO | Stock Option (right to buy) | 0 | May 24, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
LVTX | LAVA Therapeutics NV | Feb 13, 2025 | 1 | $0 | 4 | Feb 18, 2025 | Chief Financial Officer |
LVTX | LAVA Therapeutics NV | Jan 1, 2025 | 0 | $0 | 3 | Jan 2, 2025 | Chief Financial Officer |
ATRS | ANTARES PHARMA, INC. | May 24, 2022 | 9 | -$5.13M | 4 | May 26, 2022 | Executive Vice President & CFO |
ATRS | ANTARES PHARMA, INC. | Mar 3, 2022 | 2 | -$43.7K | 4 | Mar 4, 2022 | Executive Vice President & CFO |
ATRS | ANTARES PHARMA, INC. | Feb 16, 2022 | 2 | -$42.1K | 4 | Feb 18, 2022 | Executive Vice President & CFO |
ATRS | ANTARES PHARMA, INC. | Jun 10, 2021 | 4 | $250K | 4 | Jun 14, 2021 | Executive Vice President & CFO |
ATRS | ANTARES PHARMA, INC. | Jun 8, 2021 | 1 | -$52.9K | 4 | Jun 10, 2021 | Executive Vice President & CFO |